U.S. Markets closed
  • S&P 500

    3,655.04
    -38.19 (-1.03%)
     
  • Dow 30

    29,260.81
    -329.60 (-1.11%)
     
  • Nasdaq

    10,802.92
    -65.00 (-0.60%)
     
  • Russell 2000

    1,655.88
    -23.71 (-1.41%)
     
  • Crude Oil

    76.74
    +0.03 (+0.04%)
     
  • Gold

    1,633.80
    +0.40 (+0.02%)
     
  • Silver

    18.38
    -0.10 (-0.57%)
     
  • EUR/USD

    0.9615
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • GBP/USD

    1.0741
    +0.0058 (+0.54%)
     
  • USD/JPY

    144.5230
    -0.1570 (-0.11%)
     
  • BTC-USD

    19,191.91
    +410.51 (+2.19%)
     
  • CMC Crypto 200

    438.96
    +5.86 (+1.35%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Paysign (PAYS) Q2 2022 Earnings Call Transcript

·21 min read
Paysign (PAYS) Q2 2022 Earnings Call Transcript

This call may include comments that may be deemed to be forward-looking statements under the federal securities laws and the company intends that such forward-looking statements be subject to the safe harbor created thereby. All statements other than statements of fact included on this call are forward-looking statements. Such forward-looking statements include, among others, that our unrestricted cash, anticipated revenues and profits will be sufficient to sustain operations for the next 12 months; that the expected total revenue, gross profit margin, operating expenses, depreciation and amortization, stock-based compensation, adjusted EBITDA, plasma revenues, new plasma center additions, pharma revenues and new pharma co-pay customer additions for 2022 meet our expectations; that the company will continue to post year-over-year improvements; that the company's growth prospects in plasma, pharma and other prepaid business materialize; and that the company will continue to be affected by COVID-19-related labor shortages.